Velneperit
Sources
registry, as of 2018-05-01Stale
https://clinicaltrials.gov/study/NCT00788528
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 766. Conditions Obesity. The purpose of this open-label extension study is to evaluate the safety and efficacy of velneperit (S-2367) in obese subjects.
ClinicalTrials.gov NCT00788528 protocol and results modules
registry, as of 2018-05-11Stale
https://clinicaltrials.gov/study/NCT00748605
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 842. Conditions Obesity. 1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800 kcal deficit reduced calorie diet (RCD) compared with
ClinicalTrials.gov NCT00748605 protocol and results modules
registry, as of 2018-05-11Stale
https://clinicaltrials.gov/study/NCT00747929
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 724. Conditions Obesity. 1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects 2. To evaluate the safety and tolerability
ClinicalTrials.gov NCT00747929 protocol and results modules